General University Hospital Prague
Welcome,         Profile    Billing    Logout  
 8 Trials 
16 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Gompelmann, Daniela
NCT04824495: Evaluation of Inflammatory Cytokines During COVID-19

Recruiting
N/A
100
Europe
Blood sample
University of Vienna
Covid19
08/21
12/21
NCT04827667: Impact of PD1-lymphocytes in Bronchoalveolar Lavage of Patients With Lung Cancer

Recruiting
N/A
40
Europe
bronchoalveolar lavage
University of Vienna
Lung Cancer
09/21
12/21
NCT03609541: Evaluation of Biomarkers of COPD Exacerbation

Recruiting
N/A
80
Europe
Heidelberg University
SAA Level and SAA/Lipoxin A4 Ratio
06/23
06/23
NCT06056882: Simultaneous CLE Guided Crybiopsy in Patients With Pulmonary Nodules

Recruiting
N/A
20
Europe
CLE-guided cryobiopsy
University of Vienna
Pulmonary Disease
03/24
06/24
NCT06655428: The REDUCE EU Study - Endobronchial Thermal Liquid Ablation (ETLA) for the Treatment of Emphysema

Not yet recruiting
N/A
30
Europe
Endobronchial Therman Liquid Ablation (ETLA), Bronchoscopic lung volume reduction
Morair Medtech, LLC
Emphysema or COPD, Emphysema, Emphysema, Pulmonary, COPD, COPD (Chronic Obstructive Pulmonary Disease)
02/26
05/26
CLEVER, NCT06079970: Confocal Laser Endomicroscopy VERification

Recruiting
N/A
208
Europe, US, RoW
Neelde Based Confocal Laser Endomicroscopy, Conventional diagnostic bronchoscopy
Amsterdam University Medical Centers (UMC), Location Academic Medical Center (AMC), Mauna Kea Technologies
Lung Cancer, Lung Neoplasm Malignant, Carcinoma, Non-Small-Cell Lung, Neoplasm of Lung
10/25
10/25
NCT04834830: Evaluation and Importance of the PD-1/PD-L1 and the IL-10/IL-10R Axis in Malignant and Benign Pleural Effusions - a Pilot Study

Recruiting
N/A
80
Europe
Pleural effusion will be examined for various cytokines and PD1-lymphocytes.
University of Vienna
Pleural Effusion
04/22
04/22
Storring, John
SELECT MDS-1, NCT04797780 / 2020-004528-40: Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome

Recruiting
3
550
Europe, Canada, US, RoW
Tamibarotene, SY-1425, Placebo, Azacitidine
Syros Pharmaceuticals
Myelodysplastic Syndromes
11/24
02/29
NCT03421132: Multiple Myeloma Molecular Monitoring Study

Active, not recruiting
N/A
96
Canada
Horizon Health Network
Multiple Myeloma
12/24
03/26
Lejeune, Marie
SELECT MDS-1, NCT04797780 / 2020-004528-40: Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome

Recruiting
3
550
Europe, Canada, US, RoW
Tamibarotene, SY-1425, Placebo, Azacitidine
Syros Pharmaceuticals
Myelodysplastic Syndromes
11/24
02/29
Faccinetto, Céline
MANIFEST-2, NCT04603495 / 2020-001989-10: Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF)

Calendar Jan 2024 - Dec 2024: Approval for myelofibrosis
Jan 2024 - Mar 2024: From MANIFEST-2 trial in combination with ruxolitinib as a first-line treatment for patients with myelofibrosis
Feb 2024 - Feb 2024: Completion of P2b trial for JIA
Feb 2024 - Feb 2024: Exclusivity expiry in US
Active, not recruiting
3
430
Europe, Canada, US, RoW
Pelabresib, Ruxolitinib, Placebo
Constellation Pharmaceuticals
Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
08/23
12/27
SELECT MDS-1, NCT04797780 / 2020-004528-40: Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome

Recruiting
3
550
Europe, Canada, US, RoW
Tamibarotene, SY-1425, Placebo, Azacitidine
Syros Pharmaceuticals
Myelodysplastic Syndromes
11/24
02/29
Jonášová, Anna
SELECT MDS-1, NCT04797780 / 2020-004528-40: Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome

Recruiting
3
550
Europe, Canada, US, RoW
Tamibarotene, SY-1425, Placebo, Azacitidine
Syros Pharmaceuticals
Myelodysplastic Syndromes
11/24
02/29
Obbergh, Florence
SELECT MDS-1, NCT04797780 / 2020-004528-40: Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome

Recruiting
3
550
Europe, Canada, US, RoW
Tamibarotene, SY-1425, Placebo, Azacitidine
Syros Pharmaceuticals
Myelodysplastic Syndromes
11/24
02/29
HOVON 156 AML, NCT04027309 / 2018-000624-33: A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy

Active, not recruiting
3
777
Europe, RoW
Gilteritinib, ASP2215, Midostaurin, Rydapt
Stichting Hemato-Oncologie voor Volwassenen Nederland, Deutsch-Österreichische Studiengruppe Akute Myeloische Leukämie (AMLSG), Astellas Pharma Global Development, Inc.
Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2
12/24
06/33
Šestáková, Zuzana
CLEVER, NCT06079970: Confocal Laser Endomicroscopy VERification

Recruiting
N/A
208
Europe, US, RoW
Neelde Based Confocal Laser Endomicroscopy, Conventional diagnostic bronchoscopy
Amsterdam University Medical Centers (UMC), Location Academic Medical Center (AMC), Mauna Kea Technologies
Lung Cancer, Lung Neoplasm Malignant, Carcinoma, Non-Small-Cell Lung, Neoplasm of Lung
10/25
10/25

Download Options